- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06336317
Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE (ELIMINATE)
Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE - a Randomized, Double-blind, Placebo-controlled, Trial (ELIMINATE Trial)
The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are:
Does influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sara Cajander, MD
- Phone Number: +46196021000 +46196021042
- Email: sara.cajander@oru.se
Study Locations
-
-
-
Örebro, Sweden, 70185
- Recruiting
- Örebro University Hospital
-
Contact:
- Sara Cajander
- Phone Number: +46702261026
- Email: sara.cajander@oru.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a diagnosis of non-ST-segment elevation myocardial infarction
- A finalized coronary PCI
- Male or non-fertile female subjects ≥18 years. (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy)
- Written informed consent
- A CCTA can be scheduled within 7 days after PCI
Exclusion Criteria:
- Has received influenza vaccination within 6 months
- Other vaccination planned within 8 weeks (including covid-19 booster doses)
- Severe allergy to eggs or previous allergic reaction to influenza vaccine
- Cardiac surgery or staged PCI planned within 8 weeks
- Coronary stent involving the proximal RCA
- Suspicion of febrile illness or acute, ongoing infection
- Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol
- Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response
- Inability to provide informed consent
- Previous randomization in the ELIMINATE trial
- Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement.
- Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment [eGFR <30 mL/min/1.73 m2])
- Atrial fibrillation
- Uncontrolled chronic inflammatory disease
- Unable to comply with protocol requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vaccination arm
Influenza vaccine (Vaxigrip Tetra Sanofi Pasteur Europe).
|
VaxigripTetra Suspension for injection, 0,5ml prefilled syringe ATC code: J07BB02
|
Placebo Comparator: Placebo arm
Sodium Chloride (Placebo) Solution for infusion, 9mg/ml ATC code: B05BB01
|
Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The right coronary artery
Time Frame: Between baseline and 8 weeks follow up.
|
Primary endpoint definition is a difference in pericoronary adipose tissue density (perivascular fat attenuation index) around the right coronary artery (RCA) measured by repeated CCTA imaging
|
Between baseline and 8 weeks follow up.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The whole coronary tree
Time Frame: Between baseline and 8 weeks follow up.
|
Change from baseline in the average pericoronary adipose tissue density of the whole coronary tree (main epicardial arteries ≥2mm).
|
Between baseline and 8 weeks follow up.
|
Ascending aorta
Time Frame: Between baseline and 8 weeks follow up.
|
Change from baseline in the perivascular adipose tissue density of the ascending aorta
|
Between baseline and 8 weeks follow up.
|
Interleukin 1 beta (IL-1β)
Time Frame: Between baseline and 8 weeks follow up.
|
Difference in peripheral blood IL-1β concentrations
|
Between baseline and 8 weeks follow up.
|
Tumor necrosis factor alpha (TNF-α)
Time Frame: Between baseline and 8 weeks follow up.
|
Difference in peripheral blood TNF-α concentrations
|
Between baseline and 8 weeks follow up.
|
Interleukin-2 receptor (IL-2r)
Time Frame: Between baseline and 8 weeks follow up.
|
Difference in peripheral blood IL-2r concentrations
|
Between baseline and 8 weeks follow up.
|
Interleukin Interleukin-6 (IL-6 )
Time Frame: Between baseline and 8 weeks follow up.
|
Difference in peripheral blood IL-6 concentrations
|
Between baseline and 8 weeks follow up.
|
Ferritin
Time Frame: Between baseline and 8 weeks follow up.
|
Difference in peripheral blood ferritin concentrations
|
Between baseline and 8 weeks follow up.
|
Troponin-I
Time Frame: At 8 weeks follow up.
|
Differences in peripheral blood troponin-I concentrations between study groups
|
At 8 weeks follow up.
|
N-terminal pro-B-type natriuretic peptide
Time Frame: At 8 weeks follow up.
|
Differences in peripheral blood N-terminal pro-B-type natriuretic peptide concentrations between study groups
|
At 8 weeks follow up.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explorative endpoints
Time Frame: 8 weeks follow up
|
Differences in peripheral blood immune cell signatures measured by mass cytometry (CyTOF), and proteomics (O-link) will be assessed in a subset of patients with and without reduction in coronary inflammation, measured by perivascular adipose tissue density on CCTA .
Single cell RNA sequencing (sRNAseq) and measurements of cytokine profiles after in-vitro stimulation of peripheral blood mononuclear cells (PBMCs) will be performed in a subgroup of patients
|
8 weeks follow up
|
Explorative endpoints
Time Frame: Baseline
|
Exploratory proteomics by (O-link) from day 0 sampling will be performed in the whole study population to identify early biomarkers for prediction of residual inflammation.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sara Cajander, MD, Region Örebro län
- Study Chair: Ole Frøbert, professor, Region Örebro län
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELIMINATE-2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinActive, not recruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Influenza vaccine
-
Novartis VaccinesCompleted
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Emory UniversityRecruitingFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin LymphomaUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedHematologic Malignancy | Hematopoietic Stem Cell TransplantUnited States
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Sinovac Biotech Co., LtdRecruitingA Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 MonthsSeasonal InfluenzaChina
-
Sinovac Biotech Co., LtdRecruitingSeasonal InfluenzaChina
-
Novartis VaccinesCompleted
-
NovartisNovartis VaccinesCompletedInfluenza InfectionSwitzerland